Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma
ChemMedChem · 2026-04-28 · 21 (8)
DOI: 10.1002/cmdc.70283 ↗At a glance
Journal article in ChemMedChem, published online on 2026-04-25. Written by Ziyi Wang and 4 co-authors. Institution: College of Chemistry and Chemical Engineering, Guangxi University, Nanning, China. Major MEDLINE topics: Vascular Endothelial Growth Factor Receptor-2, Liver Neoplasms, Antineoplastic Agents, Drug Design. Cited 1 times so far (Crossref); 40 references. Funded by: Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Shenzhen Key Laboratory of Southern Subtropical Plant Diversity, Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province.
Abstract (original language)
Inhibition of the VEGF/VEGFR‐2 pathway is a validated strategy to suppress tumor angiogenesis and progression; however, long‐term use of several VEGFR‐2 tyrosine kinase inhibitors is limited by resistance and systemic toxicity. Here, a series of novel indolinone–matrine hybrids were designed and synthesized via a molecular hybridization strategy. The antiproliferative activities were evaluated against human hepatocellular carcinoma (HCC) cell lines (HepG‐2, HuH7, and MHCC97H). Among them, J9 showed the most potent activity with IC 50 values of 5.81, 2.14, and 3.03 μM, respectively, and relatively low cytotoxicity toward HEK‐293 cells (IC 50 = 27.90 μM) and HL7702 cells (IC50 = 52.23 μM). In HuH7 cells, J9 significantly inhibited colony formation and migration, induced G1‐phase arrest, and promoted apoptosis in a dose‐dependent manner. Western blot analysis indicated that J9 treatment was associated with downregulation of VEGFR‐2 and activation of caspase‐dependent apoptosis (increased cleaved caspase‐3 and cleaved PARP). Moreover, J9 inhibited VEGFR‐2 kinase in vitro (IC 50 = 253.51 ± 1.21 nM), and docking/MD simulations suggested stable binding within the VEGFR‐2 ATP‐binding pocket. Collectively, J9 represents a promising matrine‐derived antitumor candidate with potential VEGFR‐2‐targeting activity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Chemistry and Chemical Engineering, Guangxi University, Nanning, China.
- Medical College, Guangxi University, Nanning, China.
- School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China.
- Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Guangxi Medical University, Nanning, China.
ORCID profiles: Yongquan Wei, Lihe Jiang, Lisheng Wang
Funding
- Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
- Scientific and Technological Development under the Guidance of Central Government
Cite
APA
Wang, Z., Wei, Y., Xing, Z., Jiang, L., & Wang, L. (2026). Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma. ChemMedChem, 21(8). https://doi.org/10.1002/cmdc.70283
Vancouver
Wang Z, Wei Y, Xing Z, Jiang L, Wang L. Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma. ChemMedChem. 2026;21(8). doi:10.1002/cmdc.70283
BibTeX
@article{Wang2026,
author = {Wang, Ziyi and Wei, Yongquan and Xing, Zexu and Jiang, Lihe and Wang, Lisheng},
title = {Design, Synthesis, and Biological Evaluation of Indolin‐2‐One–Matrine Derivatives as Potential VEGFR‐2‐Targeting Agents for Hepatocellular Carcinoma},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {8},
doi = {10.1002/cmdc.70283}
}
EUVIMED